SASS-001
Phase 2Small molecule
SASS-001 is one of 37 small molecule programs targeting Sleep Apnea. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Sleep Apnea
#DrugCompanyPhaseTrials
1Diamox
TevaApproved
Aricept
EisaiApproved
Victoza
Novo NordiskApproved
Raldesy
PPragma
Approved
Lunesta
Akero TherapeuticsApproved
Propecia
OOrganon and Co
Approved
Protonix
WWyeth-Lederle Vaccines
Approved
Oxycontin
PProtega
Approved
Ultram
WWim Janssens
Approved
Nuvigil
NNuvo Research GmbH
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SASS-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShionogi Apnimed Sleep Science